MacroGenics, Inc. Hits New 52-Week High of $4.64

MacroGenics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 4.64 on May 22, 2026. This achievement marks a notable increase from its 52-week low of USD 1.19, reflecting a substantial upward movement in the stock's performance over the past year. Despite this recent high, MacroGenics has experienced a 1.09% decline in its stock price over the past year, contrasting sharply with the S&P 500's impressive 27.93% gain during the same period. The company's market capitalization stands at USD 197 million, indicating its microcap status within the industry. Financial metrics reveal that MacroGenics is currently loss-making, with a return on equity of -113.26% and a debt-to-equity ratio of -1.06. The stock does not offer a dividend yield, and its price-to-book ratio is 2.94. As the company continues to navigate the competitive landscape of pharmaceuticals and biotechnology, this recent high underscores a pivotal moment in its stock performance.